Antidoping Science: Important Lessons From the Medical Sciences

Publikationstyp:
Zeitschriftenaufsatz
Metadaten:
Autoren
  • Perikles Simon
  • Elmo WI Neuberger
  • Guan Wang
  • Yannis P Pitsiladis
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000446681200005&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1249/JSR.0000000000000521
eISSN
1537-8918
Externe Identifier
  • Clarivate Analytics Document Solution ID: GW1ZJ
  • PubMed Identifier: 30300193
ISSN
1537-890X
Ausgabe der Veröffentlichung
10
Zeitschrift
CURRENT SPORTS MEDICINE REPORTS
Paginierung
326 - 331
Datum der Veröffentlichung
2018
Status
Published
Titel
Antidoping Science: Important Lessons From the Medical Sciences
Sub types
  • Review
Ausgabe der Zeitschrift
17

Datenquelle: Web of Science (Lite)

Andere Metadatenquellen:
Abstract
<jats:p>The ineffectiveness of antidoping programs in elite sport, largely due to human and political factors, is leading to a new resolve and greater transparency of antidoping authorities and those stakeholders interested in drug-free sport. The perception by the public, athletes, and the World Anti-Doping Agency (WADA) of antidoping science and current drug testing programs in elite sport varies widely from “ineffective” to “robust and reliable.” Here, we discuss why a careful and considered reevaluation of the underlying premise of antidoping science is needed to bring this unique application of predictive/diagnostic science more in line with other areas of medicine. We show how the validity of doping tests are neither “stand-alone figures” generated under ideal laboratory conditions, nor figures that can be used in isolation to support the efficacy of the current drug testing program. Given the consequences of a failed doping test for the athlete, the sport, and multiple stakeholders (<jats:italic toggle="yes">e.g.</jats:italic>, the sponsors), there is a need for transparent decision making to ensure those affected are well informed. We identify in this perspective the minimal essential data on drug testing that should be reported by antidoping laboratories to draw meaningful conclusions about the effectiveness of specific drug testing methods to support antidoping. In the absence of information on the validity of a doping test, it is not possible to plan or conduct “intelligent testing.” It is imperative that the prevalence of doping and the likelihood of false-positive doping tests be regularly updated and made available for the wider antidoping research community to explore new approaches that could improve the validity of antidoping tests. True confirmatory testing which requires the use of different analytical technology and ideally an independent sample taken from an athlete with a positive test to transcend the present-day analysis of the B-sample. Indirect biomarkers of doping derived from new “omics”-based approaches may significantly improve the testing strategy. Biomarker molecular signatures are flexible enough to develop “normal ranges” optimized for either test sensitivity or specificity to detect a plethora of doping substances and methods.</jats:p>
Autoren
  • Perikles Simon
  • Elmo WI Neuberger
  • Guan Wang
  • Yannis P Pitsiladis
DOI
10.1249/jsr.0000000000000521
eISSN
1537-8918
ISSN
1537-890X
Ausgabe der Veröffentlichung
10
Zeitschrift
Current Sports Medicine Reports
Sprache
en
Paginierung
326 - 331
Datum der Veröffentlichung
2018
Status
Published
Herausgeber
Ovid Technologies (Wolters Kluwer Health)
Herausgeber URL
http://dx.doi.org/10.1249/jsr.0000000000000521
Datum der Datenerfassung
2023
Titel
Antidoping Science: Important Lessons From the Medical Sciences
Ausgabe der Zeitschrift
17

Datenquelle: Crossref

Abstract
The ineffectiveness of antidoping programs in elite sport, largely due to human and political factors, is leading to a new resolve and greater transparency of antidoping authorities and those stakeholders interested in drug-free sport. The perception by the public, athletes, and the World Anti-Doping Agency (WADA) of antidoping science and current drug testing programs in elite sport varies widely from "ineffective" to "robust and reliable." Here, we discuss why a careful and considered reevaluation of the underlying premise of antidoping science is needed to bring this unique application of predictive/diagnostic science more in line with other areas of medicine. We show how the validity of doping tests are neither "stand-alone figures" generated under ideal laboratory conditions, nor figures that can be used in isolation to support the efficacy of the current drug testing program. Given the consequences of a failed doping test for the athlete, the sport, and multiple stakeholders (e.g., the sponsors), there is a need for transparent decision making to ensure those affected are well informed. We identify in this perspective the minimal essential data on drug testing that should be reported by antidoping laboratories to draw meaningful conclusions about the effectiveness of specific drug testing methods to support antidoping. In the absence of information on the validity of a doping test, it is not possible to plan or conduct "intelligent testing." It is imperative that the prevalence of doping and the likelihood of false-positive doping tests be regularly updated and made available for the wider antidoping research community to explore new approaches that could improve the validity of antidoping tests. True confirmatory testing which requires the use of different analytical technology and ideally an independent sample taken from an athlete with a positive test to transcend the present-day analysis of the B-sample. Indirect biomarkers of doping derived from new "omics"-based approaches may significantly improve the testing strategy. Biomarker molecular signatures are flexible enough to develop "normal ranges" optimized for either test sensitivity or specificity to detect a plethora of doping substances and methods.
Addresses
  • Department of Sports Medicine, Institute of Sport Science, Johannes Gutenberg University Mainz, Mainz, GERMANY.
Autoren
  • Perikles Simon
  • Elmo Wi Neuberger
  • Guan Wang
  • Yannis P Pitsiladis
DOI
10.1249/jsr.0000000000000521
eISSN
1537-8918
Externe Identifier
  • PubMed Identifier: 30300193
Open access
false
ISSN
1537-890X
Ausgabe der Veröffentlichung
10
Zeitschrift
Current sports medicine reports
Schlüsselwörter
  • Humans
  • Sensitivity and Specificity
  • Substance Abuse Detection
  • Sports Medicine
  • Doping in Sports
  • Sports
  • Athletes
  • Biomarkers
Sprache
eng
Medium
Print
Paginierung
326 - 331
Datum der Veröffentlichung
2018
Status
Published
Datum der Datenerfassung
2018
Titel
Antidoping Science: Important Lessons From the Medical Sciences.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
17

Datenquelle: Europe PubMed Central

Abstract
The ineffectiveness of antidoping programs in elite sport, largely due to human and political factors, is leading to a new resolve and greater transparency of antidoping authorities and those stakeholders interested in drug-free sport. The perception by the public, athletes, and the World Anti-Doping Agency (WADA) of antidoping science and current drug testing programs in elite sport varies widely from "ineffective" to "robust and reliable." Here, we discuss why a careful and considered reevaluation of the underlying premise of antidoping science is needed to bring this unique application of predictive/diagnostic science more in line with other areas of medicine. We show how the validity of doping tests are neither "stand-alone figures" generated under ideal laboratory conditions, nor figures that can be used in isolation to support the efficacy of the current drug testing program. Given the consequences of a failed doping test for the athlete, the sport, and multiple stakeholders (e.g., the sponsors), there is a need for transparent decision making to ensure those affected are well informed. We identify in this perspective the minimal essential data on drug testing that should be reported by antidoping laboratories to draw meaningful conclusions about the effectiveness of specific drug testing methods to support antidoping. In the absence of information on the validity of a doping test, it is not possible to plan or conduct "intelligent testing." It is imperative that the prevalence of doping and the likelihood of false-positive doping tests be regularly updated and made available for the wider antidoping research community to explore new approaches that could improve the validity of antidoping tests. True confirmatory testing which requires the use of different analytical technology and ideally an independent sample taken from an athlete with a positive test to transcend the present-day analysis of the B-sample. Indirect biomarkers of doping derived from new "omics"-based approaches may significantly improve the testing strategy. Biomarker molecular signatures are flexible enough to develop "normal ranges" optimized for either test sensitivity or specificity to detect a plethora of doping substances and methods.
Autoren
  • Perikles Simon
  • Elmo Wi Neuberger
  • Guan Wang
  • Yannis P Pitsiladis
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/30300193
DOI
10.1249/JSR.0000000000000521
eISSN
1537-8918
Ausgabe der Veröffentlichung
10
Zeitschrift
Curr Sports Med Rep
Schlüsselwörter
  • Athletes
  • Biomarkers
  • Doping in Sports
  • Humans
  • Sensitivity and Specificity
  • Sports
  • Sports Medicine
  • Substance Abuse Detection
Sprache
eng
Country
United States
Paginierung
326 - 331
PII
00149619-201810000-00005
Datum der Veröffentlichung
2018
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2018
Titel
Antidoping Science: Important Lessons From the Medical Sciences.
Sub types
  • Journal Article
Ausgabe der Zeitschrift
17

Datenquelle: PubMed

Beziehungen:
Eigentum von

Werkzeuge